Misonix Presents at MicroCapClub Invitational
Company Invites Investors to View Presentation
FARMINGDALE, N.Y., Jan. 31, 2013 /PRNewswire via COMTEX/ -- Misonix, Inc.
(nasdaqgm:MSON), a surgical device company that designs, manufactures and markets
innovative therapeutic ultrasonic products worldwide for spine surgery, cranial
maxillo - facial surgery, neurosurgery, wound debridement, cosmetic surgery,
laparoscopic surgery and other surgical applications, has been selected to
present at the first ever MicroCapClub Invitational, an online forum featuring
unique microcap companies.
The Misonix presentation can be accessed at the following link:
microcapclub.com
"At MicroCapClub we have more than 160 experienced microcap investors
highlighting over 90 microcap companies in our members forum. As a group, we
thought it would be instructive to showcase a number companies we believe are
highly unique," said Ian Cassel, founder of MicroCapClub. "We have been following
Misonix since last November, and we believe the company's ultrasonic surgical
devices will continue to gain market share in 2013 and beyond."
"We are pleased to participate in this first ever event," said Michael A.
McManus, Jr., president and chief executive officer of Misonix. "We welcome the
opportunity to introduce Misonix to a universe of potential new investors."
About MicroCapClub:
The MicrocapClub (mc2) is an exclusive microcap forum focused on microcap
companies (sub $300m market cap). The MicroCapClub was created and founded by Ian
Cassel as a way to share ideas and to learn from other seasoned like-minded
microcap investors. Our goal at MicroCapClub is quality membership and quality
stock ideas. If you are an experienced microcap investor, feel free to Apply
Today. Go to microcapclub.com for additional information.
About Misonix
Misonix, Inc. designs, develops, manufactures and markets therapeutic ultrasonic
medical devices. Misonix's therapeutic ultrasonic platform is the basis for
several innovative medical technologies. Addressing a combined market estimated
to be in excess of $3 billion annually; Misonix's proprietary ultrasonic medical
devices are used for wound debridement, cosmetic surgery, neurosurgery,
laparoscopic surgery, and other surgical and medical applications. Additional
information is available on the Company's Web site at misonix.com.
Safe Harbor Statement
With the exception of historical information contained in this press release,
content herein may contain "forward looking statements" that are made pursuant to
the Safe Harbor Provisions of the Private Securities Litigation Reform Act of
1995. These statements are based on management's current expectations and are
subject to uncertainty and changes in circumstances. Investors are cautioned that
forward-looking statements involve risks and uncertainties that could cause
actual results to differ materially from the statements made. These factors
include general economic conditions, delays and risks associated with the
performance of contracts, risks associated with international sales and currency
fluctuations, uncertainties as a result of research and development, acceptable
results from clinical studies, including publication of results and
patient/procedure data with varying levels of statistical relevancy, risks
involved in introducing and marketing new products, potential acquisitions,
consumer and industry acceptance, litigation and/or court proceedings, including
the timing and monetary requirements of such activities, the timing of finding
strategic partners and implementing such relationships, regulatory risks
including approval of pending and/or contemplated 510(k) filings, the ability to
achieve and maintain profitability in the Company's business lines, and other
factors discussed in the Company's Annual Report on Form 10-K, subsequent
Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company
disclaims any obligation to update its forward-looking relationships.
Investor Relations Contacts
Misonix Contact:Lytham Partners, LLC
Richard ZarembaRobert Blum, Joe Dorame, Joe Diaz
631-694-9555602-889-9700
invest@misonix.com mson@lythampartners.com |
